Literature DB >> 18690830

Progress on kinesin spindle protein inhibitors as anti-cancer agents.

Yingjie Zhang1, Wenfang Xu.   

Abstract

The kinesin spindle protein (KSP, also known as Hs Eg5) plays an essential part in the proper separation of spindle poles and the correct formation of bipolar mitotic spindle during mitosis. Inhibition of this protein results in cells apoptosis followed by mitotic arrest and the formation of characteristic monoaster spindles. Compared with the traditional chemotherapeutic agents (taxanes, vinca alkaloids), KSP inhibitors (KSPi) will not lead to the neuropathic side effects, so KSP has become a novel and an attractive anticancer target. Accordingly, more and more interest has been focused on the development of high effective and selective KSPi. This review will focus on some kinds of KSPi on the basis of introducing structure and function of KSP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690830

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  18 in total

Review 1.  Mitosis is not a key target of microtubule agents in patient tumors.

Authors:  Edina Komlodi-Pasztor; Dan Sackett; Julia Wilkerson; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

2.  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

Authors:  H M Kantarjian; S Padmanabhan; W Stock; M S Tallman; G A Curt; J Li; A Osmukhina; K Wu; D Huszar; G Borthukar; S Faderl; G Garcia-Manero; T Kadia; K Sankhala; O Odenike; J K Altman; M Minden
Journal:  Invest New Drugs       Date:  2011-04-15       Impact factor: 3.850

3.  p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.

Authors:  Lauren Marquis; Mai Tran; Woonyoung Choi; I-Ling Lee; Dennis Huszar; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Cancer Biol Ther       Date:  2012-05-01       Impact factor: 4.742

4.  Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.

Authors:  Delany Rodriguez; Chinnasamy Ramesh; Lauren H Henson; Lori Wilmeth; Bj K Bryant; Samuel Kadavakollu; Rebecca Hirsch; Johnelle Montoya; Porsha R Howell; Jon M George; David Alexander; Dennis L Johnson; Jeffrey B Arterburn; Charles B Shuster
Journal:  Bioorg Med Chem       Date:  2011-07-30       Impact factor: 3.641

5.  Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening.

Authors:  Wei Zhang; Ling Zhai; Wenyan Lu; Rebecca J Boohaker; Indira Padmalayam; Yonghe Li
Journal:  Chem Biol Drug Des       Date:  2016-03-06       Impact factor: 2.817

6.  A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.

Authors:  Kyle Holen; Robert DiPaola; Glenn Liu; Antoinette R Tan; George Wilding; Karl Hsu; Nancy Agrawal; Cong Chen; Lingling Xue; Elizabeth Rosenberg; Mark Stein
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

7.  mRNA expression analysis of cell cycle genes in islets of pregnant mice.

Authors:  A Schraenen; G de Faudeur; L Thorrez; K Lemaire; G Van Wichelen; M Granvik; L Van Lommel; P in't Veld; F Schuit
Journal:  Diabetologia       Date:  2010-10-01       Impact factor: 10.122

8.  Cellular delivery and photochemical activation of antisense agents through a nucleobase caging strategy.

Authors:  Jeane M Govan; Rajendra Uprety; Meryl Thomas; Hrvoje Lusic; Mark O Lively; Alexander Deiters
Journal:  ACS Chem Biol       Date:  2013-08-19       Impact factor: 5.100

9.  Clotrimazole as a Cancer Drug: A Short Review.

Authors:  S Kadavakollu; C Stailey; C S Kunapareddy; S White
Journal:  Med Chem (Los Angeles)       Date:  2014

10.  KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Authors:  Ki Hyung Kim; Yanhua Xie; Ewan M Tytler; Richard Woessner; Gil Mor; Ayesha B Alvero
Journal:  J Transl Med       Date:  2009-07-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.